Background
Methods
Study population
Definitions
Statistical analysis
Results
Clinical features of participants with and without hyperuricemia
Characteristic | Male (n = 848) | Female (n = 1254) | Total (n = 2102) | ||||||
---|---|---|---|---|---|---|---|---|---|
hyperuricemia (n = 148) | No hyperuricemia (n = 700) |
P
| subtotal | hyperuricemia (n = 204) | No hyperuricemia (n = 1050) |
P
| subtotal | ||
x̄ ± s
| |||||||||
Age (yrs) | 73.5 ± 6.9 | 72.1 ± 6.8 | 0.028 | 72.3 ± 6.9 | 71.8 ± 6.0 | 70.1 ± 6.3 | 0.001 | 70.4 ± 6.2 | 71.2 ± 6.6 |
WC(cm) | 94.0 ± 8.4 | 90.6 ± 8.4 | <0.001 | 91.2 ± 8.5 | 90.3 ± 9.5 | 85.6 ± 8.6 | <0.001 | 86.4 ± 8.9 | 88.3 ± 9.1 |
BMI(kg/m2) | 25.7 ± 3.0 | 24.8 ± 3.1 | 0.002 | 24.9 ± 3.1 | 26.4 ± 3.8 | 24.8 ± 3.5 | <0.001 | 25.0 ± 3.6 | 25.0 ± 3.4 |
SBP(mm Hg) | 136.8 ± 17.5 | 136.6 ± 18.0 | 0.927 | 136.7 ± 17.9 | 141.9 ± 20.4 | 140.2 ± 20.9 | 0.285 | 140.5 ± 20.8 | 139.0 ± 19.8 |
DBP(mmHg) | 77.4 ± 9.4 | 78.6 ± 9.7 | 0.191 | 78.4 ± 9.7 | 75.9 ± 10.4 | 76.8 ± 9.9 | 0.273 | 76.6 ± 10.0 | 77.3 ± 9.9 |
TC(mmol/L) | 5.0 ± 1.1 | 4.9 ± 0.9 | 0.131 | 4.9 ± 0.9 | 5.5 ± 1.0 | 5.5 ± 1.0 | 0.550 | 5.5 ± 1.0 | 5.3 ± 1.0 |
TG(mmol/L) | 1.8 ± 1.0 | 1.5 ± 0.8 | 0.001 | 1.5 ± 0.9 | 2.1 ± 1.0 | 1.7 ± 0.9 | <0.001 | 1.8 ± 0.9 | 1.7 ± 0.9 |
HDL-C(mmol/L) | 1.2 ± 0.3 | 1.3 ± 0.4 | 0.016 | 1.3 ± 0.4 | 1.4 ± 0.4 | 1.5 ± 0.4 | <0.001 | 1.5 ± 0.4 | 1.4 ± 0.4 |
LDL-C(mmol/L) | 3.1 ± 0.9 | 3.0 ± 0.8 | 0.338 | 3.1 ± 0.8 | 3.4 ± 0.8 | 3.4 ± 0.9 | 0.506 | 3.4 ± 0.9 | 3.3 ± 0.8 |
FPG(mmol/L) | 6.0 ± 1.3 | 6.1 ± 1.6 | 0.428 | 6.1 ± 1.5 | 6.1 ± 1.3 | 6.1 ± 1.8 | 0.704 | 6.1 ± 1.8 | 6.1 ± 1.7 |
2hPG(mmol/L) | 8.1 ± 2.6 | 8.2 ± 3.0 | 0.707 | 8.2 ± 3.0 | 9.2 ± 3.3 | 8.2 ± 3.3 | <0.001 | 8.4 ± 3.3 | 8.3 ± 3.2 |
MMSE score | 27.7 ± 2.6 | 27.0 ± 3.8 | 0.014 | 27.1 ± 3.6 | 27.0 ± 3.5 | 26.7 ± 3.8 | 0.057 | 26.8 ± 3.7 | 26.9 ± 3.7 |
n (%) | |||||||||
Education ≥ 7 yrs | 124(83.8) | 576(82.3) | 0.663 | 700(82.5) | 142(69.6) | 680(64.8) | 0.183 | 822(65.6) | 1522(72.4) |
Married | 131(88.5) | 650(92.9) | 0.075 | 781(92.1) | 157(77.0) | 836(79.6) | 0.392 | 993(79.2) | 1774(84.4) |
Current smoking | 27(18.2) | 153(21.9) | 0.329 | 180(21.2) | 7(3.4) | 44(4.2) | 0.615 | 51(4.1) | 231(11.1) |
Current alcohol drinking | 58(39.2) | 267(38.1) | 0.812 | 325(38.3) | 14(6.9) | 86(8.2) | 0.522 | 100(8.0) | 425(20.2) |
Physical activity (≥0.5 h/day) | 88(59.5) | 422(60.3) | 0.852 | 510(60.1) | 121(59.3) | 603(57.4) | 0.618 | 724(57.7) | 1234(58.7) |
Family history of dementia | 10(6.8) | 32(4.6) | 0.266 | 42(5.1) | 10(4.9) | 50(4.8) | 0.932 | 60(4.8) | 102(4.9) |
Cerebral vascular disease | 28(18.9) | 90(12.9) | 0.053 | 118(13.9) | 25(12.3) | 124(11.8) | 0.857 | 149(11.9) | 267(12.7) |
Kidney disease | 31(20.9) | 52(7.4) | <0.001 | 83(9.8) | 5(2.5) | 17(1.6) | 0.408 | 22(1.8) | 105(5.0) |
Age and gender-specific prevalence of hyperuricemia and MCI of the study participants
Prevalence of hyperuricemia (%) | Prevalence of MCI (%) | |||||||
---|---|---|---|---|---|---|---|---|
Men | Female |
p
| Subtotal | Men | Female |
p
| Subtotal | |
Age group | ||||||||
60–69 yrs | 14.8 | 12.3 | 0.300 | 13.2 | 7.4 | 9.9 | 0.048 | 9.0 |
70–79 yrs | 17.8 | 18.7 | 0.704 | 18.3 | 12.9 | 22.4 | <0.001 | 18.5 |
≥ 80 yrs | 22.6 | 24.1 | 0.815 | 23.2 | 26.1 | 38.0 | 0.039 | 30.9 |
ptrend
| 0.036 | 0.002 | <0.001 | <0.001 | <0.001 | <0.001 | ||
subtotal | 17.5 | 16.3 | 0.475 | 16.7 | 12.9 | 18.0 | 0.001 | 15.9 |
Mean MMSE score and prevalence of MCI for participants with and without hyperuricemia
SUA quartiles by gender and hyperuricemia | ||||||
---|---|---|---|---|---|---|
Q1
| Q2
| Q3
| Q4
|
P
trend
| total | |
Participants without hyperuricemia | ||||||
MMSE score | ||||||
Male | 26.9 ± 3.9 | 27.0 ± 4.0 | 27.1 ± 3.4 | 27.2 ± 3.7 | 0.038 | 27.0 ± 3.8 |
Female | 26.3 ± 3.8 | 26.5 ± 4.1 | 27.0 ± 3.9 | 27.1 ± 3.2 | 0.048 | 26.7 ± 3.8 |
Subtotal | 26.6 ± 3.9 | 26.8 ± 4.1 | 27.0 ± 3.7 | 27.1 ± 3.4 | 0.031 | 26.8 ± 3.8 |
Prevalence of MCI | ||||||
Male | 28(15.7) | 23(13.7) | 24(13.6) | 21(11.9) | 0.039 | 96(13.7) |
Female | 68(25.8) | 52(20.1) | 39(14.8) | 36(13.6) | 0.008 | 195(18.6) |
Subtotal | 96(20.9) | 75(16.7) | 63(15.2) | 57(13.7) | 0.030 | 291(16.6) |
Participants with hyperuricemia | ||||||
MMSE score | ||||||
Male | 27.8 ± 3.2 | 27.7 ± 2.5 | 27.7 ± 2.8 | 27.5 ± 2.2 | 0.965 | 27.7 ± 2.6 |
Female | 26.7 ± 3.6 | 27.4 ± 2.7 | 27.2 ± 4.1 | 26.5 ± 3.4 | 0.549 | 27.0 ± 3.5 |
Subtotal | 27.2 ± 3.4 | 27.5 ± 2.5 | 27.3 ± 3.6 | 27.0 ± 3.1 | 0.772 | 27.2 ± 3.1 |
Prevalence of MCI | ||||||
Male | 5(13.5) | 3(8.1) | 4(10.8) | 1(2.7) | 0.155 | 13(8.8) |
Female | 9(18.8) | 7(13.0) | 4(7.8) | 11(21.6) | 0.854 | 31(15.2) |
Subtotal | 14(16.5) | 10(11.0) | 8(9.1) | 12(13.6) | 0.526 | 44(12.5) |
Multivariate associations of SUA level with MMSE score and MCI prevalence
SUA level (continuous) | SUA level (quartiles by gender) | ||||||
---|---|---|---|---|---|---|---|
MMSE score | β(95% CI) |
P
| Q1 | Q2 β(95% CI) | Q3 β(95% CI) | Q4 β(95% CI) |
P
trend
|
Participants with hyperuricemia | |||||||
Male | −0.03(−0.56–0.39) | 0.721 | 1.00(Ref) | 0.97(0.66–1.43) | 0.92(0.58–1.26) | 0.99(0.87–1.13) | 0.544 |
Female | −0.01(−0.43–0.37) | 0.882 | 1.00(Ref) | 1.07(0.80–1.27) | 1.05(0.78–1.31) | 1.00(0.92–1.18) | 0.922 |
Participants without hyperuricemia | |||||||
Male | 0.14(0.04–0.42) | 0.048 | 1.00(Ref) | 1.01(0.69–1.48) | 1.50(0.85–2.64) | 1.65(1.12–2.43) | 0.027 |
Female | 0.28(0.02–0.53) | 0.037 | 1.00(Ref) | 1.53(1.00–2.33) | 1.84(1.27–2.90) | 1.92(1.02–3.35) | 0.017 |
Prevalence of MCI | OR (95% CI) |
P
| Q1 | Q2 OR (95% CI) | Q3 OR (95% CI) | Q4 OR (95% CI) |
P
trend
|
Participants with hyperuricemia | |||||||
Male | 1.06(0.47–1.64) | 0.126 | 1.00(Ref) | 0.48(0.10–2.33) | 0.54(0.12–2.40) | 0.10(0.01–0.97) | 0.256 |
Female | 1.02(0.67–1.56) | 0.915 | 1.00(Ref) | 0.59(0.18–1.90) | 0.32(0.08–1.23) | 1.08(0.36–3.20) | 0.246 |
Participants without hyperuricemia | |||||||
Male | 0.82(0.68–0.99) | 0.047 | 1.00(Ref) | 0.95(0.50–1.78) | 0.91(0.49–1.70) | 0.72(0.38–1.36) | 0.025 |
Female | 0.80(0.65–0.97) | 0.034 | 1.00(Ref) | 0.87(0.45–1.70) | 0.72(0.44–1.77) | 0.64(0.39–1.06) | 0.008 |